download.jpg
AMLX 2-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Amylyx Pharmaceuticals (AMLX) Investors with Substantial Losses to Contact Firm Before Apr. 9th Deadline in Securities Fraud Class Action
April 07, 2024 13:08 ET | Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, April 07, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class Period:...
download.jpg
AMLX 5-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Amylyx Pharmaceuticals (AMLX) Investors with Substantial Losses to Contact Firm Before Apr. 9th Deadline in Securities Fraud Class Action
April 04, 2024 12:50 ET | Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, April 04, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class...
download.jpg
Amylyx Pharmaceuticals (AMLX) Tanks 80% After RELYVRIO® ALS Treatment Fails Phase 3, Follows Securities Class Action Complaint – Hagens Berman
April 01, 2024 12:59 ET | Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, April 01, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class Period:...
download.jpg
AMLX 12-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Amylyx Pharmaceuticals (AMLX) Investors with Substantial Losses to Contact Firm Before Apr. 9th Deadline in Securities Fraud Class Action
March 28, 2024 15:42 ET | Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class Period:...
download.jpg
Investors Sue Amylyx Pharmaceuticals (AMLX) After Analyst Questions RELYVRIO® Data – Hagens Berman
March 25, 2024 14:33 ET | Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, March 25, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class Period:...
download.jpg
Amylyx Pharmaceuticals (AMLX) Tanks 80% After RELYVRIO® ALS Treatment Fails Phase 3, Follows Securities Class Action Complaint – Hagens Berman
March 22, 2024 09:21 ET | Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, March 22, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class Period:...
download.jpg
Amylyx Pharmaceuticals (AMLX) Tanks 80% After RELYVRIO ALS Treatment Fails Phase 3, Follows Securities Class Action Complaint – Hagens Berman
March 18, 2024 13:43 ET | Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, March 18, 2024 (GLOBE NEWSWIRE) --  Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class Period:...
download.jpg
Amylyx Pharmaceuticals (AMLX) Tanks 80% After RELYVRIO ALS Treatment Fails Phase 3, Follows Securities Class Action Complaint – Hagens Berman
March 13, 2024 18:50 ET | Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, March 13, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class Period:...
download.jpg
Investors Sue Amylyx Pharmaceuticals (AMLX) After Analyst Questions RELYVRIO® Data – Hagens Berman
February 22, 2024 18:57 ET | Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class...
download.jpg
Amylyx Pharmaceuticals (AMLX) Sued For Securities Fraud After Analyst Questions RELYVRIO® Data – Hagens Berman
February 19, 2024 12:40 ET | Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class Period:...